Introduction: Anemia associated with chronic kidney disease is a serious complication necessitating expenditure of huge medical efforts and resources. This study investigates the role of alpha-lipoic acid (ALA) in end stage renal disease patients undergoing hemodialysis. By the virtue of its antioxidative effects, ALA is expected to act as an erythropoietin (EPO) adjuvant, and also has extended beneficial effects on endothelial dysfunction.
Methods: Forty-four patients undergoing hemodialysis and receiving EPO were randomized into two groups: the first group received ALA 600 mg once daily for 3 months; while the other group represented the control group. Parameters measured at baseline and at end of study were hemoglobin, EPO doses, EPO resistance index (ERI), iron store indices, malondialdehyde, oxidized low-density lipoprotein (ox-LDL), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and asymmetric dimethylarginine (ADMA), as well as routine laboratory follow-up.
Results: EPO doses and ERI were significantly decreased in the treatment group, while they did not change in the control group. Hemoglobin, iron store indices, malondialdehyde, oxidized ox-LDL, IL-6, TNF-α, and ADMA were similar in both treatment and control groups at baseline, and did not change by the end of study period. Likewise, routine laboratory measures were not affected by the treatment.
Conclusion: ALA could be used in hemodialysis patients to reduce requirements for EPO. However, larger and longer term studies are required to clarify the exact role of ALA in hemodialysis as well as in pre-hemodialysis patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767491 | PMC |
| http://dx.doi.org/10.2147/IJNRD.S49066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and risk factors of pre-frailty and frailty in hemodialysis patients in central China.
Sci Rep
December 2024
Hemodialysis Unit, Department of Nephrology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.
The current study was to explore the prevalence and risk factors elements of pre-frailty and frailty among patients undergoing hemodialysis (HD) in central China. A cross-sectional, multi-institutional investigation was conducted. From March to May 2024, using the convenience sampling method, a total of 408 HD patients from four hospitals in Xiangyang, China, were recruited for this study.
View Article and Find Full Text PDFA randomised controlled pilot trial protocol for patient led cognitive gamified training during haemodialysis.
Sci Rep
December 2024
University of York, York, England, UK.
Disruptions in cognitive function have been reported in individuals undergoing haemodialysis and those with chronic kidney disease. This pilot study protocol primarily assesses the feasibility and acceptability of using mobile cognitive gaming apps for patient-led cognitive training during haemodialysis sessions. The protocol consists of three phases: (1) reviewing and evaluating available cognitive gaming apps, (2) conducting focus groups/interviews with people with kidney disease to determine app preferences, and (3) undertaking a quasi-experimental randomised controlled trial to compare cognitive outcomes between a patient-led app intervention group and a standard care control group over four months.
View Article and Find Full Text PDFAnticoagulation-related complications and their outcomes in hemodialysis patients with acute kidney injury at selected hospitals in Ethiopia.
PLoS One
December 2024
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Introduction: During hemodialysis (HD), the presence of clots in the dialyzer can diminish the effective surface area of the device. In severe cases, clot formation in the circuit can halt treatment and lead to blood loss in the system. Thus, ensuring proper anticoagulation during HD is crucial to prevent clotting in the circuit while safeguarding the patient from bleeding risks.
View Article and Find Full Text PDFThe Association Between Serum Trimethylamine -Oxide and Arterial Stiffness in Chronic Peritoneal Dialysis Patients: A Cross-Sectional Study.
Toxins (Basel)
December 2024
Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.
Trimethylamine -oxide (TMAO), a gut microbiome-derived metabolite, participates in the atherogenesis and vascular stiffening that is closely linked with cardiovascular (CV) complications and related deaths in individuals with kidney failure undergoing peritoneal dialysis (PD) therapy. In these patients, arterial stiffness (AS) is also an indicator of adverse CV outcomes. This study assessed the correlation between serum TMAO concentration quantified with high-performance liquid chromatography and mass spectrometry and central AS measured by carotid-femoral pulse wave velocity (cfPWV) in patients with chronic PD.
View Article and Find Full Text PDFAssociation of Protein Energy Wasting and Oxidative Stress Markers in Peritoneal Dialysis.
Iran J Kidney Dis
December 2024
Department of Health Sciences-Illness as an Individual Process, University Center of Tonala, University of Guadalajara, Guadalajara, Jalisco, Mexico.
Introduction: Protein-energy wasting (PEW) is highly prevalent among patients undergoing peritoneal dialysis (PD), and it has been proposed that oxidative stress (OS) may contribute to its pathogenesis. This study was an attempt to determine the association between the presence of PEW and OS levels in PD patients.
Methods: This analytical cross-sectional study involved 62 clinically stable PD patients aged ≥ 18 years, between September 2017 and July 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!